WO2019034945A1 - Dynamic host-guest interactive system - Google Patents
Dynamic host-guest interactive system Download PDFInfo
- Publication number
- WO2019034945A1 WO2019034945A1 PCT/IB2018/055375 IB2018055375W WO2019034945A1 WO 2019034945 A1 WO2019034945 A1 WO 2019034945A1 IB 2018055375 W IB2018055375 W IB 2018055375W WO 2019034945 A1 WO2019034945 A1 WO 2019034945A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- molecule
- guest
- host
- combination
- imager
- Prior art date
Links
- 230000002452 interceptive effect Effects 0.000 title claims abstract description 39
- 238000003384 imaging method Methods 0.000 claims abstract description 70
- 230000008685 targeting Effects 0.000 claims abstract description 51
- 239000003814 drug Substances 0.000 claims abstract description 50
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 43
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 claims description 52
- 210000004027 cell Anatomy 0.000 claims description 44
- ZDOBFUIMGBWEAB-XGFHMVPTSA-N cucurbit[7]uril Chemical compound N1([C@H]2[C@H]3N(C1=O)CN1[C@H]4[C@H]5N(C1=O)CN1[C@H]6[C@H]7N(C1=O)CN1[C@H]8[C@H]9N(C1=O)CN1[C@H]%10[C@H]%11N(C1=O)CN([C@@H]1N(C%12=O)CN%11C(=O)N%10CN9C(=O)N8CN7C(=O)N6CN5C(=O)N4CN3C(=O)N2C2)C3=O)CN4C(=O)N5[C@H]6[C@@H]4N2C(=O)N6CN%12[C@@H]1N3C5 ZDOBFUIMGBWEAB-XGFHMVPTSA-N 0.000 claims description 30
- 230000003993 interaction Effects 0.000 claims description 23
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 18
- 125000005647 linker group Chemical group 0.000 claims description 13
- -1 metallacrowns Chemical class 0.000 claims description 12
- 238000009825 accumulation Methods 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 238000012876 topography Methods 0.000 claims description 10
- 229920000858 Cyclodextrin Polymers 0.000 claims description 9
- VTJUKNSKBAOEHE-UHFFFAOYSA-N calixarene Chemical class COC(=O)COC1=C(CC=2C(=C(CC=3C(=C(C4)C=C(C=3)C(C)(C)C)OCC(=O)OC)C=C(C=2)C(C)(C)C)OCC(=O)OC)C=C(C(C)(C)C)C=C1CC1=C(OCC(=O)OC)C4=CC(C(C)(C)C)=C1 VTJUKNSKBAOEHE-UHFFFAOYSA-N 0.000 claims description 9
- 150000003983 crown ethers Chemical class 0.000 claims description 9
- 229940097362 cyclodextrins Drugs 0.000 claims description 9
- 150000004032 porphyrins Chemical class 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 9
- 150000003384 small molecules Chemical class 0.000 claims description 9
- HTJMXYRLEDBSLT-UHFFFAOYSA-N 1,2,4,5-tetrazine Chemical compound C1=NN=CN=N1 HTJMXYRLEDBSLT-UHFFFAOYSA-N 0.000 claims description 8
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 8
- 229960003805 amantadine Drugs 0.000 claims description 8
- MSBXTPRURXJCPF-DQWIULQBSA-N cucurbit[6]uril Chemical compound N1([C@@H]2[C@@H]3N(C1=O)CN1[C@@H]4[C@@H]5N(C1=O)CN1[C@@H]6[C@@H]7N(C1=O)CN1[C@@H]8[C@@H]9N(C1=O)CN([C@H]1N(C%10=O)CN9C(=O)N8CN7C(=O)N6CN5C(=O)N4CN3C(=O)N2C2)C3=O)CN4C(=O)N5[C@@H]6[C@H]4N2C(=O)N6CN%10[C@H]1N3C5 MSBXTPRURXJCPF-DQWIULQBSA-N 0.000 claims description 7
- 108020004414 DNA Proteins 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 6
- 230000000996 additive effect Effects 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 239000012099 Alexa Fluor family Substances 0.000 claims description 4
- FOYVTVSSAMSORJ-UHFFFAOYSA-N atto 655 Chemical compound OC(=O)CCCN1C(C)(C)CC(CS([O-])(=O)=O)C2=C1C=C1OC3=CC4=[N+](CC)CCCC4=CC3=NC1=C2 FOYVTVSSAMSORJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000004913 cyclooctene Substances 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 3
- 108020004459 Small interfering RNA Proteins 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 210000003463 organelle Anatomy 0.000 claims description 3
- 238000012377 drug delivery Methods 0.000 abstract description 22
- 210000000170 cell membrane Anatomy 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 53
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 108010009711 Phalloidine Proteins 0.000 description 26
- 239000000243 solution Substances 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 21
- 102000007469 Actins Human genes 0.000 description 19
- 108010085238 Actins Proteins 0.000 description 19
- 238000000034 method Methods 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 239000002105 nanoparticle Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 238000010857 super resolution fluorescence microscopy Methods 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000011550 stock solution Substances 0.000 description 9
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 8
- 239000010931 gold Substances 0.000 description 8
- 229910052737 gold Inorganic materials 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000000835 fiber Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000004397 blinking Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- 238000010870 STED microscopy Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- ZRKMQKLGEQPLNS-UHFFFAOYSA-N 1-Pentanethiol Chemical compound CCCCCS ZRKMQKLGEQPLNS-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000006862 quantum yield reaction Methods 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000010869 super-resolution microscopy Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940086542 triethylamine Drugs 0.000 description 2
- JQZIKLPHXXBMCA-UHFFFAOYSA-N triphenylmethanethiol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(S)C1=CC=CC=C1 JQZIKLPHXXBMCA-UHFFFAOYSA-N 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NULDEVQACXJZLL-UHFFFAOYSA-N 2-(2-aminoethyldisulfanyl)ethylazanium;chloride Chemical compound Cl.NCCSSCCN NULDEVQACXJZLL-UHFFFAOYSA-N 0.000 description 1
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008846 dynamic interplay Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000001454 recorded image Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
Definitions
- the present invention generally relates to the field of imaging, sensing and therapeutics delivery. More specifically, the present invention relates to a dynamic host-guest interactive system that possesses unique characteristics and finds utility in multitude of areas, specifically, in imaging, sensing and site directed drug delivery.
- host-guest chemistry describes complexes that are composed of two or more molecules or ions that are held together in unique structural relationships by non-covalent forces.
- the non-covalent forces can be hydrogen bonds, ionic bonds, van-der-Waals forces, and hydrophobic interactions.
- the tailoring of host molecules or compounds with other agents can be of great importance and recent advancement seek to incorporate utilization of host-guest chemistry in a variety of biological applications.
- Super-resolution fluorescence microscopy provides in-situ visualization of molecular organization and their interactions beyond the classical diffraction limit of light.
- the super-resolution imaging techniques rely on switching molecules between fluorescent ON and OFF states to consecutively localize individual molecules at nanometer precision and eventually obtaining a super-resolved image.
- switching between ON and OFF states is usually achieved externally, either through a targeted mechanism, for example, Stimulated Emission Depletion Microscopy (STED), or through a stochastic approach, for example, Stochastic Optical Reconstruction Microscopy (STORM) (Huang, B., Jones, S. A., Brandenburg, B. & Zhuang, X.
- STED Stimulated Emission Depletion Microscopy
- STORM Stochastic Optical Reconstruction Microscopy
- dyes with photo-switchable property are essential and specialized buffer conditions (e.g. buffer with reducing/oxidizing agents) have to be employed to get optimal results. Additionally, initial exposure of the specimen to high-power laser illumination is necessary for converting molecules to fluorescence OFF-states.
- the specialized buffer conditions along with the requirement of high-power laser illumination limit their compatibility with live cell imaging experiments.
- PAINT points accumulation for imaging in nanoscale topography
- PAINT represents a conceptually different and easy-to-implement strategy to perform super-resolution microscopy
- Scharonov et al Proc. Natl. Acad. Sci. USA 2006, 103, 18911-18916; Jungmann et al, Nano Lett. 2010, 10, 4756-4761; Agasti et al, Chem. Sci. 2017, 8, 3080- 3091.
- imaging is carried out by using an influx of diffusing fluorescent molecules that interact transiently with the sample.
- This strategy benefits by their use of conventional fluorophores and importantly, the implementation of PAINT does not require any specialized equipment or experimental conditions to switch fluorophores between ON- and OFF-states.
- PAINT strategy was applied to image lipid bilayers and double stranded DNA by using dye molecules (Kuo et al, J. Am. Chem. Soc. 2011, 133, 4664-4667; Schoen et al, Nano Lett. 2011, 11, 4008-4011).
- DNA and protein fragment based PAINT probes i.e. DNA-PAINT and IRIS
- DNA-PAINT and IRIS DNA-PAINT and IRIS
- digestion by nucleases and proteases compromises the stability of these probes under intracellular environment. Therefore, despite being simple and easy-to- implement, the application of PAINT based strategies in live cell microscopy remains challenging.
- cytoskeletal proteins perform a variety of cellular activities and thus imaging of cytoskeleton proteins in living cells leads to the understanding of various intracellular dynamics.
- researchers have attempted to image actin, an important cytoskeletal protein by labeling actin utilizing various complicated techniques such as microinjection or electroporation due to the serious issue of membrane impermeability of the targeting agents (e.g. phalloidin) or the organic fluorophores.
- researchers also followed alternative strategy of fusing GFP with actin filaments following the transfection method.
- these methods are laborious and time consuming which might alter the fate of the live cells.
- An object of the present disclosure is to provide a dynamic host-guest interactive system that can overcome the deficiencies associated with the prior art.
- Another object of the present disclosure is to provide a dynamic host-guest interactive system for single molecule fluorescence ON and OFF blinking.
- Another object of the present disclosure is to provide a dynamic host-guest interactive system for single molecule based super-resolution imaging.
- Another object of the present disclosure is to provide a dynamic host-guest interactive system for live cell super-resolution imaging.
- Another object of the present disclosure is to provide a dynamic host-guest interactive system for carrying membrane impermeable materials into the intracellular environment.
- Another object of the present disclosure is to provide a dynamic host-guest interactive system for drug delivery.
- Another object of the present disclosure is to provide an imaging and a drug delivery system that can utilize supramolecular host-guest interaction.
- Another object of the present disclosure is to provide an imaging and a drug delivery system that exhibits desired specificity.
- Another object of the present disclosure is to provide an imaging and a drug delivery system that gives image of the biological system without utilization of any of an external stimuli or an additive.
- Another object of the present disclosure is to provide an imaging and a drug delivery system that offers improved resolution without any complex instrumentation or specialized experimental conditions.
- Another object of the present disclosure is to provide an imaging and a delivery system that is easy to implement.
- Another object of the present disclosure is to provide an imaging and a delivery system that is cost-effective.
- the present invention generally relates to the field of imaging and drug delivery. More specifically, the present invention relates to a dynamic host-guest interactive system that possesses unique characteristics and finds utility in multitude of areas, specifically, in imaging and site directed drug delivery.
- An aspect of the present disclosure provides a dynamic host-guest interactive system including at least one host molecule; and at least one guest molecule wherein the at least one host molecule interacts with the at least one guest molecule through non-covalent forces, and wherein the at least one host molecule is associated with any or a combination of at least one targeting moiety and at least one therapeutic agent with proviso that when the host molecule is associated with the at least one targeting moiety, the guest molecule is associated with at least one imager, and when the host molecule is associated with the at least one therapeutic agent, the guest molecule is associated with at least one targeting moiety, and when the host molecule is associated with a combination of the at least one therapeutic agent and the at least one targeting moiety, the guest molecule is associated with at least one imager.
- the at least one host molecule is selected from any or a combination of cucurbituril, cyclodextrins, calixarenes, pillararenes, porphyrins, metallacrowns, crown ethers, cyclotriveratrylenes, cryptophanes, cyclophanes and carcerands.
- the at least one guest molecule is selected from any or a combination of propylamine, hexamethylenediamine and adamantylamine.
- the cucurbituril is CB[7], and the association of CB[7] with the at least one therapeutic agent increases solubility of said at least one therapeutic agent.
- the association of CB[7] with the at least one therapeutic agent affords protection to said at least one therapeutic agent from degradation in a biological medium.
- the system affords site specific delivery of the at least one therapeutic agent by targeting tissue and organelles.
- the system affords a convenient route to any or a combination of cell surface engineering and cell surface modification.
- the host molecule associated with said at least one therapeutic agent exhibits capability to bind with proteins to afford protection to pharmacokinetics of the at least one therapeutic agent.
- the system affords delivery of any or a combination of DNA, RNA, siRNA and protein by non-covalent interaction thereof with the host molecule.
- the at least one guest molecule is associated with the at least one imager through a first linking moiety and wherein the at least one host molecule is associated with the at least one targeting moiety through a second linking moiety, and wherein the first linking moiety and the second linking moiety is selected independently from any or a combination of trara-cyclooctene (TCO), 1,2,4,5-tetrazine (TZ) and N- hydroxysuccinimide (NHS).
- TCO trara-cyclooctene
- TZ 1,2,4,5-tetrazine
- NHS N- hydroxysuccinimide
- the interaction of the at least one guest molecule associated with the imager with the at least one host molecule through the non- covalent forces effects ON-state of the imager associated with the guest molecule when subjected to points accumulation for imaging in nanoscale topography (PAINT).
- PAINT nanoscale topography
- the imager associated with the at least one guest molecule exhibits OFF-state in an event of absence of interaction between the at least one guest molecule and the at least one host molecule through the non-covalent forces when subjected to points accumulation for imaging in nanoscale topography (PAINT).
- PAINT nanoscale topography
- the ON-state and OFF-state of the imager associated with the at least one guest molecule is effected without utilization of any of an external stimuli and an additive.
- Another aspect of the present disclosure provides a dynamic host-guest interactive system including at least one host molecule; and at least one guest molecule wherein the at least one host molecule is associated with at least one targeting moiety, and wherein the at least one guest molecule is associated with at least one imager, and wherein the at least one imager associated with the at least one guest molecule exhibits OFF-state in an event of absence of non-covalent forces operative between the at least one guest molecule and the at least one host molecule, and wherein non-covalent interaction of the at least one guest molecule associated with the imager with the at least one host molecule effects ON-state of the imager associated with the guest molecule, when subjected to points accumulation for imaging in nanoscale topography (PAF T).
- PAF T nanoscale topography
- the at least one host molecule is selected from any or a combination of cucurbiturils, cyclodextrins, calixarenes, pillararenes, porphyrins, metallacrowns, crown ethers, cyclotriveratrylenes, cryptophanes, cyclophanes and carcerands.
- the at least one guest molecule is selected from any or a combination of propylamine, hexamethylenediamine and adamantylamine.
- the at least one imager is selected from any or a combination of Alexa Fluor, Cy5, Atto 655 and Rhodamine.
- the at least one targeting moiety is selected from any or a combination of antibodies and small molecules.
- Still further aspect of the present disclosure provides a dynamic host-guest interactive system including at least one host molecule; and at least one guest molecule wherein the at least one host molecule is associated with at least one therapeutic agent, and wherein said at least one guest molecule is associated with at least one targeting moiety, and wherein said at least one guest molecule is associated with said at least one targeting moiety through covalent bond.
- the at least one host molecule is selected from any or a combination of cucurbiturils, cyclodextrins, calixarenes, pillararenes, porphyrins, metallacrowns, crown ethers, cyclotriveratrylenes, cryptophanes, cyclophanes and carcerands.
- the at least one guest molecule is selected from any or a combination of propylamine, hexamethylenediamine and adamantylamine.
- the at least one targeting moiety is selected from any or a combination of antibodies and small molecules.
- FIG. 1A illustrates an exemplary snippet depicting the general principle behind utilization of the dynamic host-guest interactive system, realized in accordance with embodiments of the present disclosure, in imaging.
- FIG. IB illustrates an exemplary snippet depicting a series of images, wherein in each frame only a fraction of the molecules are stochastically in ON-state, in accordance with embodiments of the present disclosure.
- FIG. 1C illustrates exemplary snippets depicting accuracy of the imaging technique, realized in accordance with embodiments of the present disclosure, in comparison to traditional imaging technique.
- FIG. 2 illustrates an exemplary snippet depicting the general principle behind utilization of the dynamic host-guest interactive system, realized in accordance with embodiments of the present disclosure, in drug delivery.
- FIG. 3A illustrate an exemplary image depicting F-actin fibers in MEF cells stained with CB[7] conjugated phalloidin (scale bar 1 ⁇ ) utilizing super-resolution fluorescence microscopy, in accordance with an embodiment of the present disclosure.
- FIG. 3B illustrate an exemplary image (zoomed-in view, scale bar 500 nm) depicting F-actin fibers in MEF cells utilizing traditional imaging technique (diffraction limited image).
- FIG. 3C illustrate an exemplary image (zoomed-in view of image illustrated in FIG. 3A, scale bar 500 nm) depicting F-actin fibers in MEF cells, in accordance with an embodiment of the present disclosure.
- FIG. 3D illustrates an exemplary graph depicting comparison of super-resolution fluorescence microscopy of F-actin, in accordance with an embodiment of the present disclosure, with the results obtained from traditional imaging technique.
- FIG. 4A illustrate an exemplary image depicting super-resolution fluorescence microscopy of phalloidin targeted F-actin, in accordance with an embodiment of the present disclosure.
- FIG. 4B illustrate an exemplary image of phalloidin targeted F-actin utilizing traditional imaging technique.
- FIG. 4C illustrates an exemplary graph depicting comparison of super-resolution fluorescence microscopy of phalloidin targeted F-actin, in accordance with an embodiment of the present disclosure, with the results obtained from traditional imaging technique.
- the present invention generally relates to the field of imaging and drug delivery. More specifically, the present invention relates to a dynamic host-guest interactive system that possesses unique characteristics and finds utility in multitude of areas, specifically, in imaging and site directed drug delivery.
- An aspect of the present disclosure provides a dynamic host-guest interactive system including at least one host molecule; and at least one guest molecule, wherein the at least one host molecule interacts with the at least one guest molecule through non-covalent forces, and wherein the at least one host molecule is associated with any or a combination of at least one targeting moiety and at least one therapeutic agent with proviso that when the host molecule is associated with the at least one targeting moiety, the guest molecule is associated with at least one imager, and when the host molecule is associated with the at least one therapeutic agent, the guest molecule is associated with at least one targeting moiety, and when the host molecule is associated with a combination of the at least one therapeutic agent and the at least one targeting moiety, the guest molecule is associated with at least one imager.
- the at least one host molecule is selected from any or a combination of cucurbituril, cyclodextrins, calixarenes, pillararenes, porphyrins, metallacrowns, crown ethers, cyclotriveratrylenes, cryptophanes, cyclophanes and carcerands.
- the at least one host molecule is cucurbituril.
- the at least one host molecule is cucurbit[n]uril, wherein n ranges from 5 to 10.
- the at least one host molecule is cucurbit[7]uril (hereinafter referred to as CB[7]).
- CB[7] cucurbit[7]
- any other host molecule as known to or appreciated by a person skilled in the art, can be utilized to serve its intended purpose, as laid down in the present disclosure, without departing from the scope and spirit of the present invention.
- the at least one guest molecule is selected from any or a combination of propylamine, hexamethylenediamine (HMD) and adamantylamine.
- HMD hexamethylenediamine
- adamantylamine any other guest molecule, as known to or appreciated by a person skilled in the art, can be utilized to serve its intended purpose, as laid down in the present disclosure, without departing from the scope and spirit of the present invention.
- the at least one guest molecule is associated with the at least one imager through a first linking moiety and the at least one host molecule is associated with the at least one targeting moiety through a second linking moiety.
- the first linking moiety and the second linking moiety is selected independently from any or a combination of tram'-cyclooctene (TCO), 1,2,4,5-tetrazine (TZ) and N-hydroxysuccinimide (NHS).
- TCO tram'-cyclooctene
- TZ 1,2,4,5-tetrazine
- NHS N-hydroxysuccinimide
- any other linking moiety as known to or appreciated by a person skilled in the art, can be utilized to serve its intended purpose, as laid down in the present disclosure, without departing from the scope and spirit of the present invention.
- the at least one imager is selected from any or a combination of fluorophores like Alexa Fluor, Cy5, Atto 655 and Rhodamine, but not limited thereto.
- fluorophores like Alexa Fluor, Cy5, Atto 655 and Rhodamine, but not limited thereto.
- any other imager as known to or appreciated by a person skilled in the art, can be utilized to serve its intended purpose as laid down in embodiments of the present disclosure without departing from the scope and the spirit of the present invention.
- the at least one targeting moiety is selected from any or a combination of antibodies, small molecules and nanoparticles, but not limited thereto. Any other targeting moiety, as known to or appreciated by a person skilled in the art, can be utilized to serve its intended purpose as laid down in embodiments of the present disclosure without departing from the scope and the spirit of the present invention.
- any one or a plurality of therapeutic agents can be utilized for the present invention to effect advantages realized herein in accordance with embodiments of the present disclosure.
- the therapeutic agent(s) can be any of anti-cancer agents to effect site-directed delivery thereof, in accordance with embodiments of the present disclosure.
- the therapeutic agent(s) can be a diagnostic agent.
- the therapeutic agent(s) can be a contrast media.
- the cucurbituril is CB[7], and the association of CB[7] with the at least one therapeutic agent increases solubility of said at least one therapeutic agent.
- the association of CB[7] with the at least one therapeutic agent affords protection to said at least one therapeutic agent from degradation in a biological medium.
- the system affords site specific delivery of the at least one therapeutic agent by targeting tissue and organelles.
- the system affords a convenient route to any or a combination of cell surface engineering and cell surface modification.
- the host molecule associated with said at least one therapeutic agent exhibits capability to bind with proteins to afford protection to pharmacokinetics of the at least one therapeutic agent.
- the system affords delivery of any or a combination of DNA, RNA, siRNA and protein by non-covalent interaction thereof with the host molecule.
- the interaction of the at least one guest molecule associated with the imager with the at least one host molecule through the non-covalent forces effects ON-state of the imager associated with the guest molecule when subjected to points accumulation for imaging in nanoscale topography (PAINT).
- the imager associated with the at least one guest molecule exhibits OFF-state in an event of absence of interaction between the at least one guest molecule and the at least one host molecule through the non-covalent forces when subjected to points accumulation for imaging in nanoscale topography (PAINT).
- the ON-state and OFF-state of the imager associated with the at least one guest molecule is effected without utilization of any of an external stimuli and an additive.
- FIG. 1A illustrates an exemplary snippet depicting the general principle behind utilization of the dynamic host-guest interactive system, realized in accordance with embodiments of the present disclosure, in imaging.
- a host molecule (102) is targeted to the biomolecule of interest (106) through the use of a targeting agent/moiety (104).
- a guest molecule (108), associated with a fluorophore/imager (110) is introduced into the medium, it interacts transiently with the host through non-covalent forces operative therebetween.
- the imaging process includes recording a series of images where in each frame only a fraction of the molecules are stochastically in ON state.
- the imaging technique utilizes the dynamic interaction between a macrocyclic host (or similar supramolecular system) and fluorescently labeled guest molecule to obtain autonomous ON/OFF-switching of fluorescence under physiological condition without using any additives.
- a macrocyclic host or similar supramolecular system
- fluorescently labeled guest molecule to obtain autonomous ON/OFF-switching of fluorescence under physiological condition without using any additives.
- the inventors of the present disclosure for the first time establish dynamic host-guest interactive system mediated autonomous single molecule blinking with prescribed brightness and frequency, enabling two-dimensional (2D) and three-dimensional (3D) super-resolution imaging of biomolecules in cells.
- the inventors of the present disclosure for the first time establish that cell permeable nature of host-guest interactive system along with their interaction specificity in biological environment allow the instant technique to be applicable in live-cell super-resolution microscopy. Supramolecular interaction between the host-guest system enables super-resolution fluorescence imaging of molecules inside living cells, fixed cells and tissue sample.
- the dynamic host-guest interactive system realized in accordance with embodiments of the present disclosure, represents the first of its kind of synthetic PAINT labels that are small, membrane-permeable, provide interaction specificity, and can be applied to live-cell super-resolution imaging.
- FIG. 1C illustrates exemplary snippets depicting accuracy of the imaging technique, realized in accordance with embodiments of the present disclosure, in comparison to traditional imaging technique (diffraction limited image).
- the at least one host molecule is selected from any or a combination of cucurbiturils, cyclodextrins, calixarenes, pillararenes, porphyrins, metallacrowns, crown ethers, cyclotriveratrylenes, cryptophanes, cyclophanes and carcerands.
- any other host molecule as known to or appreciated by a person skilled in the art can be utilized to serve its intended purpose as laid down in the present disclosure without departing from the scope and spirit of the invention.
- the at least one guest molecule is selected from any or a combination of propylamine, hexamethylenediamine and adamantylamine.
- any other guest molecule as known to or appreciated by a person skilled in the art can be utilized to serve its intended purpose as laid down in the present disclosure without departing from the scope and spirit of the invention.
- the at least one imager is selected from any or a combination of Alexa Fluor, Cy5, Atto 655, Rhodamine and the like fluorophores.
- Alexa Fluor Cy5
- Atto 655 Rhodamine
- Rhodamine Rhodamine
- any other imager as known to or appreciated by a person skilled in the art can be utilized to serve its intended purpose as laid down in the present disclosure without departing from the scope and spirit of the invention.
- the at least one targeting moiety is selected from any or a combination of antibodies and small molecules.
- any other targeting moiety/agent as known to or appreciated by a person skilled in the art can be utilized to serve its intended purpose as laid down in the present disclosure without departing from the scope and spirit of the invention.
- the inventors of the present disclosure establish dynamic host-guest interactive system mediated site directed drug delivery, optionally, along with imaging of the same.
- non-covalent host-guest interactions provide efficient and novel means to deliver phalloidin or like therapeutic agents of interest to the site of interest.
- utilization of non-covalent interaction between guest molecule(s) associated with targeting moiety(ies) such as nanoparticles and the likes and host molecule(s) associated with therapeutic agent can allow therapeutic agent(s) with relatively less cell membrane permeability to be delivered to the site of interest (e.g. cytosolic delivery).
- FIG. 2 illustrates an exemplary snippet depicting the general principle behind utilization of the dynamic host-guest interactive system, realized in accordance with embodiments of the present disclosure, in drug delivery. As can be seen from FIG.
- a dynamic host-guest interactive system including at least one host molecule (206); and at least one guest molecule (208) wherein the at least one host molecule (206) is associated with at least one therapeutic agent (204), and wherein the at least one guest molecule (208) is associated with at least one targeting moiety (210), and wherein the at least one guest molecule (208) is associated with the at least one targeting moiety (210) through a covalent bond.
- the at least one host molecule is selected from any or a combination of cucurbiturils, cyclodextrins, calixarenes, pillararenes, porphyrins, metallacrowns, crown ethers, cyclotriveratrylenes, cryptophanes, cyclophanes and carcerands, but not limited thereto.
- the at least one guest molecule is selected from any or a combination of propylamine, hexamethylenediamine and adamantylamine, but not limited thereto.
- the at least one targeting moiety is selected from any or a combination of antibodies, small molecules and nanoparticles, but not limited thereto.
- EXAMPLE 1 Imaging of F-actin fibers in MEF cells utilizing a dynamic host-guest interactive system including CB[7] as a host molecule conjugated with Phalloidin (a targeting moiety), and hexamethylene diamine (a guest molecule) conjugated with Cy5 (an imager)
- CB[7] was attached with tram'-cyclooctene (TCO) through functional modification of CB[7], and the 1,2,4,5-tetrazine (Tz) was anchored onto Phalloidin using its amine functionality.
- CB[7] conjugated Phalloidin was prepared via strain promoted cyclo-addition reaction between TCO and Tz.
- the acidic solution was evaporated using rotary evaporator upto 2 ml and 250 ml methanol was added to it.
- the resulted precipitate was allowed to settle down for overnight.
- the supernatant was decanted and remaining volume was centrifuged at 5500 rpm to get a light-yellow colored precipitate.
- the precipitate was washed with 50 ml of methanol for 3 times and finally dried in vacuum oven for overnight.
- Imaging was performed using a Zeiss oil-immersion TIRF objective (alpha Plan-apochromat DIC lOOx/1.46 Oil DIC M27, numerical aperture (NA) 1.46 oil). Fluorescence light was spectrally filtered with emission filters (MBS-561+EF BP 570-650/LP 750 for laser line 561 and MBS-642+EF LP 655 for laser line 642) and imaged on an electron-multiplying charge-coupled device (EMCCD) camera (Andor iXon DU897, quantum yield >90%, 512 x 512 pixels). In vitro single molecule data was then analysed by using a custom-programmed software package named 'Picasso' .
- EMCCD electron-multiplying charge-coupled device
- FIG. 3A illustrates an exemplary super-resolution image of F-actin fibers in MEF cells stained with CB[7] conjugated phalloidin (scale bar 1 ⁇ ).
- FIG. 3B illustrate an exemplary image (zoomed-in view, scale bar 500 nm) depicting F-actin fibers in MEF cells utilizing traditional imaging technique (diffraction limited image).
- FIG. 3D illustrates an exemplary graph depicting comparison of super-resolution fluorescence microscopy of F- actin, cross-section profile of a single filament dl in FIG. 3C, that shows a Gaussion fit with FWHM of 29.87+2.91 nm) in accordance with an embodiment of the present disclosure, with the results obtained from traditional imaging technique.
- HMD hexamethylene diamine
- HeLa cells epidermal, human cervical cancer cell line
- the cells were cultured in a humidified atmosphere (5% C02) at 37°C and grown in Dulbecco's Modified Eagle's Medium (DMEM, high glucose) supplemented with 10% fetal bovine serum (FBS) (Gibco, USA), 2 mM Glutamax (Invitrogen, USA) and 1% antibiotics (100 U/ml penicillin, 100 ⁇ g/ml streptomycin and 0.25 ⁇ g/ml amphotericin) (Gibco, USA).
- DMEM Dulbecco's Modified Eagle's Medium
- FBS fetal bovine serum
- 2 mM Glutamax Invitrogen, USA
- antibiotics 100 U/ml penicillin, 100 ⁇ g/ml streptomycin and 0.25 ⁇ g/ml amphotericin
- the cells were washed 3 times with DPBS (Gibco, USA), trypsinized and suspended in culture medium. Afterward, cells were then counted and then in a typical experiment, -25,000 cells/well were plated in 8- well chamber slide system (Eppendorf). The cells were then maintained again in a humidified atmosphere (37°C, 5% C02) for 24 h to reach -60% confluence. Thereafter, cells were used for imaging experiment.
- DPBS Gibco, USA
- HMD functionalized Gold nanoparticles and CB[7] conjugated with Phalloidin were prepared in accordance with the procedure provided in Example 2 above. Further, HMD conjugated Rhodamine was prepared to effect imaging of F-actin fibers in MEF cells.
- Rhodamine maleimide 37.62 ⁇ g from 1.33 mg ml-1 stock solution in PBS (pH 7.4), 0.068 ⁇
- PBS pH 7.4
- a stock solution of Compound 6 63 ⁇ from 1 mg ml-1 stock solution in PBS (pH 7.4), 0.2042 ⁇
- Imaging with super-resolution fluorescence microscopy technique After nanoparticle mediated delivery of Phalloidin-CB[7] conjugate utilizing methodology as provided in Example 2 hereinabove, cells were immediately incubated with 10 nM PBS solution of silicon Rhodamine conjuagted HMD imager. The imaging was started immediately after the imager incubation. The images were captured using an inverted Zeiss ELYRA PS 1 microscope, capable to illuminating the sample with TIRF illumination mode. The microscope was fitted with a definite focus system to eliminate z drift. 642 nm (150 mW) laser has been used for excitation of Alexa 647 dye.
- Imaging was performed using a Zeiss oil-immersion TIRF objective (alpha Plan-apochromat DIC lOOx/1.46 Oil DIC M27, numerical aperture (NA) 1.46 oil). Fluorescence light was spectrally filtered with emission filter (MBS-642+EF LP 655 for laser line 642) and imaged on an electron -multiplying charge-coupled device (EMCCD) camera (Andor iXon DU897, quantum yield >90%, 512 x 512 pixels). Camera readout rate was 1 MHz at 16 bit. The recorded image dimension was 51.10 ⁇ x 51.10 ⁇ . EMCCD camera gain was kept at 200 during image acquisition.
- EMCCD electron -multiplying charge-coupled device
- FIG. 4A illustrate an exemplary image depicting super-resolution fluorescence microscopy of phalloidin targeted F-actin (scale bar: 5 ⁇ ), in accordance with an embodiment of the present disclosure.
- Non-covalent interaction mediated delivery of phalloidin allowed the access to the CB[7] functionality for imaging via super-resolution fluorescence microscopy technique.
- FIG. 4B illustrate an exemplary image of phalloidin targeted F-actin (scale bar: 5 ⁇ ) utilizing traditional imaging technique. As can be seen from FIG. 4A and FIG. 4B, a significant improvement of resolution and much sharper image from live cell could be obtained utilizing the technique in accordance with embodiments of the present disclosure.
- FIG. 4C illustrates an exemplary graph depicting comparison of super-resolution fluorescence microscopy of phalloidin targeted F-actin (cross-section profile of an actin filament - region marked with a square in FIG. 4A and FIG.
- FIG. 4C shows a Gaussion fit with full width at half maximum (FWHM) of 59.39+1.86 nm for image obtained in accordance with embodiment of the present disclosure as compare to a FWHM of 358.27+8 nm for the diffraction limited image.
- FWHM full width at half maximum
- the present disclosure provides a dynamic host-guest interactive system that can overcomes the deficiencies associated with the prior art.
- the present disclosure provides a dynamic host-guest interactive system for imaging.
- the present disclosure provides a dynamic host-guest interactive system for drug delivery.
- the present disclosure provides an imaging and a drug delivery system that can utilize supramolecular host-guest interaction.
- the present disclosure provides an imaging and a drug delivery system that exhibits desired specificity.
- the present disclosure provides an imaging and a drug delivery system that gives image of the biological system without utilization of any of an external stimuli or an additive.
- the present disclosure provides an imaging and a drug delivery system that offers improved resolution without any complex instrumentation or specialized experimental conditions.
- the present disclosure provides an imaging and a delivery system that is easy to implement.
- the present disclosure provides an imaging and a delivery system that is cost- effective.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Ceramic Engineering (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to a dynamic host-guest interactive system that possesses unique characteristics and finds utility in multitude of areas, specifically, in imaging and site directed drug delivery. An aspect of the present disclosure provides a dynamic host-guest interactive system including a host molecule and a guest molecule interacting with each other through non-covalent forces, wherein the host molecule is associated with any or a combination of a targeting moiety and a therapeutic agent with proviso that when the host molecule is associated with the targeting moiety, the guest molecule is associated with an imager, and when the host molecule is associated with the therapeutic agent, the guest molecule is associated with the targeting moiety, and when the host molecule is associated with a combination of the therapeutic agent and the targeting moiety, the guest molecule is associated with the imager. Another aspect provides a dynamic host-guest interactive system for site specific drug delivery of relatively less cell membrane permeable drug(s).
Description
DYNAMIC HOST-GUEST INTERACTIVE SYSTEM TECHNICAL FIELDS
[0001] The present invention generally relates to the field of imaging, sensing and therapeutics delivery. More specifically, the present invention relates to a dynamic host-guest interactive system that possesses unique characteristics and finds utility in multitude of areas, specifically, in imaging, sensing and site directed drug delivery.
BACKGROUND
[0002] Background description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
[0003] In supramolecular chemistry, host-guest chemistry describes complexes that are composed of two or more molecules or ions that are held together in unique structural relationships by non-covalent forces. The non-covalent forces can be hydrogen bonds, ionic bonds, van-der-Waals forces, and hydrophobic interactions. The tailoring of host molecules or compounds with other agents can be of great importance and recent advancement seek to incorporate utilization of host-guest chemistry in a variety of biological applications.
[0004] Super-resolution fluorescence microscopy provides in-situ visualization of molecular organization and their interactions beyond the classical diffraction limit of light. In general, the super-resolution imaging techniques rely on switching molecules between fluorescent ON and OFF states to consecutively localize individual molecules at nanometer precision and eventually obtaining a super-resolved image. In most of traditional techniques, switching between ON and OFF states is usually achieved externally, either through a targeted mechanism, for example, Stimulated Emission Depletion Microscopy (STED), or through a stochastic approach, for example, Stochastic Optical Reconstruction Microscopy (STORM) (Huang, B., Jones, S. A., Brandenburg, B. & Zhuang, X. Whole-cell 3D STORM reveals interactions between cellular structures with nanometer-scale resolution. Nat. Methods, 5, 1047-1052 (2008); Betzig, E. et al. Imaging intracellular fluorescent proteins at nanometer resolution. Science 313, 1642-1645 (2006); Hell, S.W. & Wichmann, J. Breaking the diffraction resolution limit by stimulated emission: stimulated emission-depletion fluorescence microscopy. Opt. Lett. 19, 780-782 (1994); Hell, S.W. Far-field optical nanoscopy. Science 316, 1153-1158 (2007)). Although these techniques provide improved
resolution, they suffer from several shortcomings. Often times they are difficult for the standard laboratories to apply due their complex requirements. For example, the instrumentation for STED microscopy is complicated and cost intensive. In STORM microscopy, dyes with photo-switchable property are essential and specialized buffer conditions (e.g. buffer with reducing/oxidizing agents) have to be employed to get optimal results. Additionally, initial exposure of the specimen to high-power laser illumination is necessary for converting molecules to fluorescence OFF-states. The specialized buffer conditions along with the requirement of high-power laser illumination limit their compatibility with live cell imaging experiments.
[0005] PAINT (points accumulation for imaging in nanoscale topography) represents a conceptually different and easy-to-implement strategy to perform super-resolution microscopy (Sharonov et al, Proc. Natl. Acad. Sci. USA 2006, 103, 18911-18916; Jungmann et al, Nano Lett. 2010, 10, 4756-4761; Agasti et al, Chem. Sci. 2017, 8, 3080- 3091). In this strategy, imaging is carried out by using an influx of diffusing fluorescent molecules that interact transiently with the sample. This strategy benefits by their use of conventional fluorophores and importantly, the implementation of PAINT does not require any specialized equipment or experimental conditions to switch fluorophores between ON- and OFF-states. Initially, PAINT strategy was applied to image lipid bilayers and double stranded DNA by using dye molecules (Kuo et al, J. Am. Chem. Soc. 2011, 133, 4664-4667; Schoen et al, Nano Lett. 2011, 11, 4008-4011). However, lack of specificity hindered the use of these PAINT-compatible dyes for imaging other biomolecules of interest. Recently, DNA and protein fragment based PAINT probes (i.e. DNA-PAINT and IRIS) were introduced to achieve specificity. However, the DNA and protein probes are membrane- impermeable. Further, digestion by nucleases and proteases compromises the stability of these probes under intracellular environment. Therefore, despite being simple and easy-to- implement, the application of PAINT based strategies in live cell microscopy remains challenging.
[0006] Another significant challenge in biology is to deliver relatively membrane impermeable materials to live cell to achieve therapeutic benefit or to visualize specific biomolecules inside living cells through targeted labeling. For example, cytoskeletal proteins perform a variety of cellular activities and thus imaging of cytoskeleton proteins in living cells leads to the understanding of various intracellular dynamics. Researchers have attempted to image actin, an important cytoskeletal protein by labeling actin utilizing various complicated techniques such as microinjection or electroporation due to the serious issue of
membrane impermeability of the targeting agents (e.g. phalloidin) or the organic fluorophores. Researchers also followed alternative strategy of fusing GFP with actin filaments following the transfection method. However, these methods are laborious and time consuming which might alter the fate of the live cells.
[0007] There is, therefore, a need in the art to develop a dynamic host-guest interactive system that possesses unique characteristics and which can find utility in a multitude of areas, specifically, in imaging and site directed drug delivery. The present disclosure satisfies the existing needs, as well as others and alleviates the shortcomings of the traditional imaging and drug delivery techniques.
OBJECTS OF THE INVENTION
[0008] An object of the present disclosure is to provide a dynamic host-guest interactive system that can overcome the deficiencies associated with the prior art.
[0009] Another object of the present disclosure is to provide a dynamic host-guest interactive system for single molecule fluorescence ON and OFF blinking.
[0010] Another object of the present disclosure is to provide a dynamic host-guest interactive system for single molecule based super-resolution imaging.
[0011] Another object of the present disclosure is to provide a dynamic host-guest interactive system for live cell super-resolution imaging.
[0012] Another object of the present disclosure is to provide a dynamic host-guest interactive system for carrying membrane impermeable materials into the intracellular environment.
[0013] Another object of the present disclosure is to provide a dynamic host-guest interactive system for drug delivery.
[0014] Another object of the present disclosure is to provide an imaging and a drug delivery system that can utilize supramolecular host-guest interaction.
[0015] Another object of the present disclosure is to provide an imaging and a drug delivery system that exhibits desired specificity.
[0016] Another object of the present disclosure is to provide an imaging and a drug delivery system that gives image of the biological system without utilization of any of an external stimuli or an additive.
[0017] Another object of the present disclosure is to provide an imaging and a drug delivery system that offers improved resolution without any complex instrumentation or specialized experimental conditions.
[0018] Another object of the present disclosure is to provide an imaging and a delivery system that is easy to implement.
[0019] Another object of the present disclosure is to provide an imaging and a delivery system that is cost-effective.
SUMMARY
[0020] The present invention generally relates to the field of imaging and drug delivery. More specifically, the present invention relates to a dynamic host-guest interactive system that possesses unique characteristics and finds utility in multitude of areas, specifically, in imaging and site directed drug delivery.
[0021] An aspect of the present disclosure provides a dynamic host-guest interactive system including at least one host molecule; and at least one guest molecule wherein the at least one host molecule interacts with the at least one guest molecule through non-covalent forces, and wherein the at least one host molecule is associated with any or a combination of at least one targeting moiety and at least one therapeutic agent with proviso that when the host molecule is associated with the at least one targeting moiety, the guest molecule is associated with at least one imager, and when the host molecule is associated with the at least one therapeutic agent, the guest molecule is associated with at least one targeting moiety, and when the host molecule is associated with a combination of the at least one therapeutic agent and the at least one targeting moiety, the guest molecule is associated with at least one imager.
[0022] In an embodiment, the at least one host molecule is selected from any or a combination of cucurbituril, cyclodextrins, calixarenes, pillararenes, porphyrins, metallacrowns, crown ethers, cyclotriveratrylenes, cryptophanes, cyclophanes and carcerands. In an embodiment, the at least one guest molecule is selected from any or a combination of propylamine, hexamethylenediamine and adamantylamine. In an embodiment, the cucurbituril is CB[7], and the association of CB[7] with the at least one therapeutic agent increases solubility of said at least one therapeutic agent. In an embodiment, the association of CB[7] with the at least one therapeutic agent affords protection to said at least one therapeutic agent from degradation in a biological medium. In an embodiment, the system affords site specific delivery of the at least one therapeutic agent by targeting tissue and organelles. In an embodiment, the system affords a convenient route to any or a combination of cell surface engineering and cell surface modification. In an embodiment, the host molecule associated with said at least one therapeutic agent exhibits
capability to bind with proteins to afford protection to pharmacokinetics of the at least one therapeutic agent. In an embodiment, the system affords delivery of any or a combination of DNA, RNA, siRNA and protein by non-covalent interaction thereof with the host molecule.
[0023] In an embodiment, the at least one guest molecule is associated with the at least one imager through a first linking moiety and wherein the at least one host molecule is associated with the at least one targeting moiety through a second linking moiety, and wherein the first linking moiety and the second linking moiety is selected independently from any or a combination of trara-cyclooctene (TCO), 1,2,4,5-tetrazine (TZ) and N- hydroxysuccinimide (NHS). In an embodiment, the interaction of the at least one guest molecule associated with the imager with the at least one host molecule through the non- covalent forces effects ON-state of the imager associated with the guest molecule when subjected to points accumulation for imaging in nanoscale topography (PAINT).
[0024] In an embodiment, the imager associated with the at least one guest molecule exhibits OFF-state in an event of absence of interaction between the at least one guest molecule and the at least one host molecule through the non-covalent forces when subjected to points accumulation for imaging in nanoscale topography (PAINT). In an embodiment, the ON-state and OFF-state of the imager associated with the at least one guest molecule is effected without utilization of any of an external stimuli and an additive.
[0025] Another aspect of the present disclosure provides a dynamic host-guest interactive system including at least one host molecule; and at least one guest molecule wherein the at least one host molecule is associated with at least one targeting moiety, and wherein the at least one guest molecule is associated with at least one imager, and wherein the at least one imager associated with the at least one guest molecule exhibits OFF-state in an event of absence of non-covalent forces operative between the at least one guest molecule and the at least one host molecule, and wherein non-covalent interaction of the at least one guest molecule associated with the imager with the at least one host molecule effects ON-state of the imager associated with the guest molecule, when subjected to points accumulation for imaging in nanoscale topography (PAF T). In an embodiment, the at least one host molecule is selected from any or a combination of cucurbiturils, cyclodextrins, calixarenes, pillararenes, porphyrins, metallacrowns, crown ethers, cyclotriveratrylenes, cryptophanes, cyclophanes and carcerands. In an embodiment, the at least one guest molecule is selected from any or a combination of propylamine, hexamethylenediamine and adamantylamine. In an embodiment, the at least one imager is selected from any or a combination of Alexa Fluor,
Cy5, Atto 655 and Rhodamine. In an embodiment, the at least one targeting moiety is selected from any or a combination of antibodies and small molecules.
[0026] Still further aspect of the present disclosure provides a dynamic host-guest interactive system including at least one host molecule; and at least one guest molecule wherein the at least one host molecule is associated with at least one therapeutic agent, and wherein said at least one guest molecule is associated with at least one targeting moiety, and wherein said at least one guest molecule is associated with said at least one targeting moiety through covalent bond. In an embodiment, the at least one host molecule is selected from any or a combination of cucurbiturils, cyclodextrins, calixarenes, pillararenes, porphyrins, metallacrowns, crown ethers, cyclotriveratrylenes, cryptophanes, cyclophanes and carcerands. In an embodiment, the at least one guest molecule is selected from any or a combination of propylamine, hexamethylenediamine and adamantylamine. In an embodiment, the at least one targeting moiety is selected from any or a combination of antibodies and small molecules.
[0027] Various objects, features, aspects and advantages of the inventive subject matter will become more apparent from the following detailed description of preferred embodiments, along with the accompanying drawing figures in which like numerals represent like components.
BRIEF DESCRIPTION OF THE DRAWINGS
[0028] The accompanying drawings are included to provide a further understanding of the present disclosure, and are incorporated in and constitute a part of this specification. The drawings illustrate exemplary embodiments of the present disclosure and, together with the description, serve to explain the principles of the present disclosure.
[0029] FIG. 1A illustrates an exemplary snippet depicting the general principle behind utilization of the dynamic host-guest interactive system, realized in accordance with embodiments of the present disclosure, in imaging.
[0030] FIG. IB illustrates an exemplary snippet depicting a series of images, wherein in each frame only a fraction of the molecules are stochastically in ON-state, in accordance with embodiments of the present disclosure.
[0031] FIG. 1C illustrates exemplary snippets depicting accuracy of the imaging technique, realized in accordance with embodiments of the present disclosure, in comparison to traditional imaging technique.
[0032] FIG. 2 illustrates an exemplary snippet depicting the general principle behind utilization of the dynamic host-guest interactive system, realized in accordance with embodiments of the present disclosure, in drug delivery.
[0033] FIG. 3A illustrate an exemplary image depicting F-actin fibers in MEF cells stained with CB[7] conjugated phalloidin (scale bar 1 μπι) utilizing super-resolution fluorescence microscopy, in accordance with an embodiment of the present disclosure.
[0034] FIG. 3B illustrate an exemplary image (zoomed-in view, scale bar 500 nm) depicting F-actin fibers in MEF cells utilizing traditional imaging technique (diffraction limited image).
[0035] FIG. 3C illustrate an exemplary image (zoomed-in view of image illustrated in FIG. 3A, scale bar 500 nm) depicting F-actin fibers in MEF cells, in accordance with an embodiment of the present disclosure.
[0036] FIG. 3D illustrates an exemplary graph depicting comparison of super-resolution fluorescence microscopy of F-actin, in accordance with an embodiment of the present disclosure, with the results obtained from traditional imaging technique.
[0037] FIG. 4A illustrate an exemplary image depicting super-resolution fluorescence microscopy of phalloidin targeted F-actin, in accordance with an embodiment of the present disclosure.
[0038] FIG. 4B illustrate an exemplary image of phalloidin targeted F-actin utilizing traditional imaging technique.
[0039] FIG. 4C illustrates an exemplary graph depicting comparison of super-resolution fluorescence microscopy of phalloidin targeted F-actin, in accordance with an embodiment of the present disclosure, with the results obtained from traditional imaging technique.
DETAILED DESCRIPTION
[0040] The following is a detailed description of embodiments of the disclosure depicted in the accompanying drawings. The embodiments are in such detail as to clearly communicate the disclosure. However, the amount of detail offered is not intended to limit the anticipated variations of embodiments; on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the present disclosure as defined by the appended claims.
[0041] Each of the appended claims defines a separate invention, which for infringement purposes is recognized as including equivalents to the various elements or limitations specified in the claims. Depending on the context, all references below to the "invention"
may in some cases refer to certain specific embodiments only. In other cases it will be recognized that references to the "invention" will refer to subject matter recited in one or more, but not necessarily all, of the claims.
[0042] As used in the description herein and throughout the claims that follow, the meaning of "a," "an," and "the" includes plural reference unless the context clearly dictates otherwise. Also, as used in the description herein, the meaning of "in" includes "in" and "on" unless the context clearly dictates otherwise.
[0043] All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. "such as") provided with respect to certain embodiments herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
[0044] Various terms as used herein are shown below. To the extent a term used in a claim is not defined below, it should be given the broadest definition persons in the pertinent art have given that term as reflected in printed publications and issued patents at the time of filing.
[0045] The present invention generally relates to the field of imaging and drug delivery. More specifically, the present invention relates to a dynamic host-guest interactive system that possesses unique characteristics and finds utility in multitude of areas, specifically, in imaging and site directed drug delivery.
[0046] An aspect of the present disclosure provides a dynamic host-guest interactive system including at least one host molecule; and at least one guest molecule, wherein the at least one host molecule interacts with the at least one guest molecule through non-covalent forces, and wherein the at least one host molecule is associated with any or a combination of at least one targeting moiety and at least one therapeutic agent with proviso that when the host molecule is associated with the at least one targeting moiety, the guest molecule is associated with at least one imager, and when the host molecule is associated with the at least one therapeutic agent, the guest molecule is associated with at least one targeting moiety, and when the host molecule is associated with a combination of the at least one therapeutic agent and the at least one targeting moiety, the guest molecule is associated with at least one imager.
[0047] In an embodiment, the at least one host molecule is selected from any or a combination of cucurbituril, cyclodextrins, calixarenes, pillararenes, porphyrins, metallacrowns, crown ethers, cyclotriveratrylenes, cryptophanes, cyclophanes and carcerands. In an embodiment, the at least one host molecule is cucurbituril. In an embodiment, the at least one host molecule is cucurbit[n]uril, wherein n ranges from 5 to 10. In an embodiment, the at least one host molecule is cucurbit[7]uril (hereinafter referred to as CB[7]). However, any other host molecule, as known to or appreciated by a person skilled in the art, can be utilized to serve its intended purpose, as laid down in the present disclosure, without departing from the scope and spirit of the present invention.
[0048] In an embodiment, the at least one guest molecule is selected from any or a combination of propylamine, hexamethylenediamine (HMD) and adamantylamine. However, any other guest molecule, as known to or appreciated by a person skilled in the art, can be utilized to serve its intended purpose, as laid down in the present disclosure, without departing from the scope and spirit of the present invention.
[0049] In an embodiment, the at least one guest molecule is associated with the at least one imager through a first linking moiety and the at least one host molecule is associated with the at least one targeting moiety through a second linking moiety. In an embodiment, the first linking moiety and the second linking moiety is selected independently from any or a combination of tram'-cyclooctene (TCO), 1,2,4,5-tetrazine (TZ) and N-hydroxysuccinimide (NHS). However, any other linking moiety, as known to or appreciated by a person skilled in the art, can be utilized to serve its intended purpose, as laid down in the present disclosure, without departing from the scope and spirit of the present invention.
[0050] In an embodiment, the at least one imager is selected from any or a combination of fluorophores like Alexa Fluor, Cy5, Atto 655 and Rhodamine, but not limited thereto. However, any other imager, as known to or appreciated by a person skilled in the art, can be utilized to serve its intended purpose as laid down in embodiments of the present disclosure without departing from the scope and the spirit of the present invention.
[0051] In an embodiment, the at least one targeting moiety is selected from any or a combination of antibodies, small molecules and nanoparticles, but not limited thereto. Any other targeting moiety, as known to or appreciated by a person skilled in the art, can be utilized to serve its intended purpose as laid down in embodiments of the present disclosure without departing from the scope and the spirit of the present invention.
[0052] In an embodiment, any one or a plurality of therapeutic agents can be utilized for the present invention to effect advantages realized herein in accordance with embodiments of
the present disclosure. The term "therapeutic agent" and "drug" used throughout the present disclosure, interchangeably and synonymously, includes within its scope, any natural, semisynthetic or synthetic molecule that may bear therapeutic efficacy or which may aid in diagnosis, prognosis, prevention or cure of any ailments or disease or disorder in a mammal. In an exemplary embodiment, the therapeutic agent(s) can be any of anti-cancer agents to effect site-directed delivery thereof, in accordance with embodiments of the present disclosure. In an exemplary embodiment, the therapeutic agent(s) can be a diagnostic agent. In an exemplary embodiment, the therapeutic agent(s) can be a contrast media.
[0053] In an embodiment, the cucurbituril is CB[7], and the association of CB[7] with the at least one therapeutic agent increases solubility of said at least one therapeutic agent. In an embodiment, the association of CB[7] with the at least one therapeutic agent affords protection to said at least one therapeutic agent from degradation in a biological medium. In an embodiment, the system affords site specific delivery of the at least one therapeutic agent by targeting tissue and organelles. In an embodiment, the system affords a convenient route to any or a combination of cell surface engineering and cell surface modification. In an embodiment, the host molecule associated with said at least one therapeutic agent exhibits capability to bind with proteins to afford protection to pharmacokinetics of the at least one therapeutic agent. In an embodiment, the system affords delivery of any or a combination of DNA, RNA, siRNA and protein by non-covalent interaction thereof with the host molecule.
[0054] In an embodiment, the interaction of the at least one guest molecule associated with the imager with the at least one host molecule through the non-covalent forces effects ON-state of the imager associated with the guest molecule when subjected to points accumulation for imaging in nanoscale topography (PAINT). In an embodiment, the imager associated with the at least one guest molecule exhibits OFF-state in an event of absence of interaction between the at least one guest molecule and the at least one host molecule through the non-covalent forces when subjected to points accumulation for imaging in nanoscale topography (PAINT). In an embodiment, the ON-state and OFF-state of the imager associated with the at least one guest molecule is effected without utilization of any of an external stimuli and an additive.
[0055] FIG. 1A illustrates an exemplary snippet depicting the general principle behind utilization of the dynamic host-guest interactive system, realized in accordance with embodiments of the present disclosure, in imaging. As can be seen from FIG. 1A, a host molecule (102) is targeted to the biomolecule of interest (106) through the use of a targeting agent/moiety (104). Once a guest molecule (108), associated with a fluorophore/imager (110)
is introduced into the medium, it interacts transiently with the host through non-covalent forces operative therebetween. In the unbound state only background fluorescence (OFF state) is observed (shown as 112), whereas a bright fluorescence emission (ON state) is detected upon transient immobilization of the imager through specific binding with host (shown as 114). This autonomous fluorescence blinking provides the foundation for the super-resolution imaging. As illustrated in FIG. IB, the imaging process includes recording a series of images where in each frame only a fraction of the molecules are stochastically in ON state.
[0056] A person skilled in the art would immediately realize that the imaging technique, realized in accordance with embodiments of the present disclosure, utilizes the dynamic interaction between a macrocyclic host (or similar supramolecular system) and fluorescently labeled guest molecule to obtain autonomous ON/OFF-switching of fluorescence under physiological condition without using any additives. Surprisingly, through coupling of macrocyclic host with antibodies or small molecule based targeting platforms, the inventors of the present disclosure for the first time establish dynamic host-guest interactive system mediated autonomous single molecule blinking with prescribed brightness and frequency, enabling two-dimensional (2D) and three-dimensional (3D) super-resolution imaging of biomolecules in cells. Further, the inventors of the present disclosure for the first time establish that cell permeable nature of host-guest interactive system along with their interaction specificity in biological environment allow the instant technique to be applicable in live-cell super-resolution microscopy. Supramolecular interaction between the host-guest system enables super-resolution fluorescence imaging of molecules inside living cells, fixed cells and tissue sample. The dynamic host-guest interactive system, realized in accordance with embodiments of the present disclosure, represents the first of its kind of synthetic PAINT labels that are small, membrane-permeable, provide interaction specificity, and can be applied to live-cell super-resolution imaging.
[0057] Accordingly, another aspect of the present disclosure provides a dynamic host- guest interactive system including at least one host molecule; and at least one guest molecule wherein the at least one host molecule is associated with at least one targeting moiety, and wherein the at least one guest molecule is associated with at least one imager, and wherein the at least one imager associated with the at least one guest molecule exhibits OFF-state in an event of absence of non-covalent forces operative between the at least one guest molecule and the at least one host molecule, and wherein non-covalent interaction of the at least one guest molecule associated with the imager with the at least one host molecule effects ON-
state of the imager associated with the guest molecule, when subjected to points accumulation for imaging in nanoscale topography (PAINT). FIG. 1C illustrates exemplary snippets depicting accuracy of the imaging technique, realized in accordance with embodiments of the present disclosure, in comparison to traditional imaging technique (diffraction limited image).
[0058] In an embodiment, the at least one host molecule is selected from any or a combination of cucurbiturils, cyclodextrins, calixarenes, pillararenes, porphyrins, metallacrowns, crown ethers, cyclotriveratrylenes, cryptophanes, cyclophanes and carcerands. However, any other host molecule as known to or appreciated by a person skilled in the art can be utilized to serve its intended purpose as laid down in the present disclosure without departing from the scope and spirit of the invention.
[0059] In an embodiment, the at least one guest molecule is selected from any or a combination of propylamine, hexamethylenediamine and adamantylamine. However, any other guest molecule as known to or appreciated by a person skilled in the art can be utilized to serve its intended purpose as laid down in the present disclosure without departing from the scope and spirit of the invention.
[0060] In an embodiment, the at least one imager is selected from any or a combination of Alexa Fluor, Cy5, Atto 655, Rhodamine and the like fluorophores. However, any other imager as known to or appreciated by a person skilled in the art can be utilized to serve its intended purpose as laid down in the present disclosure without departing from the scope and spirit of the invention.
[0061] In an embodiment, the at least one targeting moiety is selected from any or a combination of antibodies and small molecules. However, any other targeting moiety/agent as known to or appreciated by a person skilled in the art can be utilized to serve its intended purpose as laid down in the present disclosure without departing from the scope and spirit of the invention.
[0062] Further, the inventors of the present disclosure, for the first time, establish dynamic host-guest interactive system mediated site directed drug delivery, optionally, along with imaging of the same. Interestingly and surprisingly, non-covalent host-guest interactions provide efficient and novel means to deliver phalloidin or like therapeutic agents of interest to the site of interest. Further, it is established by the inventors of the present disclosure that utilization of non-covalent interaction between guest molecule(s) associated with targeting moiety(ies) such as nanoparticles and the likes and host molecule(s) associated with therapeutic agent can allow therapeutic agent(s) with relatively less cell membrane permeability to be delivered to the site of interest (e.g. cytosolic delivery).
[0063] Accordingly, another aspect of the present disclosure provides a dynamic host- guest interactive system including at least one host molecule; and at least one guest molecule wherein the at least one host molecule is associated with at least one therapeutic agent, and wherein the at least one guest molecule is associated with at least one targeting moiety, and wherein the at least one guest molecule is associated with the at least one targeting moiety through covalent bond. FIG. 2 illustrates an exemplary snippet depicting the general principle behind utilization of the dynamic host-guest interactive system, realized in accordance with embodiments of the present disclosure, in drug delivery. As can be seen from FIG. 2, a dynamic host-guest interactive system including at least one host molecule (206); and at least one guest molecule (208) wherein the at least one host molecule (206) is associated with at least one therapeutic agent (204), and wherein the at least one guest molecule (208) is associated with at least one targeting moiety (210), and wherein the at least one guest molecule (208) is associated with the at least one targeting moiety (210) through a covalent bond.
[0064] In an embodiment, the at least one host molecule is selected from any or a combination of cucurbiturils, cyclodextrins, calixarenes, pillararenes, porphyrins, metallacrowns, crown ethers, cyclotriveratrylenes, cryptophanes, cyclophanes and carcerands, but not limited thereto. In an embodiment, the at least one guest molecule is selected from any or a combination of propylamine, hexamethylenediamine and adamantylamine, but not limited thereto. In an embodiment, the at least one targeting moiety is selected from any or a combination of antibodies, small molecules and nanoparticles, but not limited thereto.
EXAMPLES
[0065] EXAMPLE 1 : Imaging of F-actin fibers in MEF cells utilizing a dynamic host-guest interactive system including CB[7] as a host molecule conjugated with Phalloidin (a targeting moiety), and hexamethylene diamine (a guest molecule) conjugated with Cy5 (an imager)
[0066] Preparation of CB[7] conjugated with Phalloidin and Hexamethylene Diamine (HMD) conjugated with Cy5
[0067] As illustrated in Scheme 1 below, CB[7] was attached with tram'-cyclooctene (TCO) through functional modification of CB[7], and the 1,2,4,5-tetrazine (Tz) was anchored onto Phalloidin using its amine functionality. CB[7] conjugated Phalloidin was prepared via strain promoted cyclo-addition reaction between TCO and Tz.
Scheme 1: Synthesis of CB[7] conjugated with a targeting moiety
[0068] Synthesis of CB[7]-OH: CB[7] (250 mg, 0.215 mmol) was taken in a 50 ml quartz tube. It was dissolved in 40 ml solution of miliQ water and 10 M HC1 solution (1/1 vol. %) under argon atmosphere. Sample was sonicated for a brief period to ensure that all the CB[7] was solubilized before the addition of a solution of hydrogen peroxide (49 μΐ from 30% solution, 0.215 mmol). Then the solution was subjected to UV irradiation at wavelength of 250-400 nm (450 W) under vigorous stirring condition for 7.5 h. After that, the acidic solution was evaporated using rotary evaporator upto 2 ml and 250 ml methanol was added to
it. The resulted precipitate was allowed to settle down for overnight. Next, the supernatant was decanted and remaining volume was centrifuged at 5500 rpm to get a light-yellow colored precipitate. The precipitate was washed with 50 ml of methanol for 3 times and finally dried in vacuum oven for overnight.
CB[7] CB[7]-OH
[0069] Synthesis of CB[7]-0-allyl: NaH (64.8 mg, 60% dispersion in mineral oil, 1.62 mmol) was added to 6 ml anhydrous DMSO solution of CB[7]-OH (191 mg, 0.162 mmol) under dry argon atmosphere. The reaction was stirred for 1 h at room temperature. Allyl bromide (138.86 μΐ, 1.62 mmol) was then added to this reaction mixture maintaining the temperature of reaction mixture at 0°C during addition. The reaction was further stirred at room temperature for 18 h. After that the reaction mixture was poured into 200 ml diethyl ether, sonicated and allowed to stand for overnight. Then the supernatant was decanted and the remaining volume was centrifuged at 5500 rpm to get white precipitate. Then it was washed with 200 ml diethyl ether for 3 times and finally dried under high vacuum.
CB[7]-0-allyl
[0070] Synthesis of CB[7]-NH2: CB[7]-0 Allyl (124 mg, 0.1017 mmol) was taken in a quartz cuvette and dissolved in 3 ml miliQ water. Cystamine hydrochloride (115.53 mg, 1.017 mmol) was added to it and the reaction mixture was purged with N2 gas followed by subjected to UV irradiation at wavelength of 254-400 nm (450 W) for 12.5 h. After completion of the reaction, 50 ml ethanol was added to get white precipitate. The precipitate was allowed to settle down for overnight. Then supernatant was decanted and remaining volume was centrifuged at 5500 rpm to get solid precipitate. Next, it was washed with 50 ml ethanol and dried under high vacuum.
[0071] Synthesis of CB[7]-PEG-TCO: CB[7]- H2 (1.7 mg, 1.297 μιηοΐ) was taken in 3 ml glass vial and dissolved in 200 μΐ dry DMF. Et3N (1.8 ul, 12.97 μιηοΐ) was added to it.
TCO-PEG- HS ester (1 mg, 1.945 μιηοΐ) was dissolved in 100 μΐ DMF in another vial and added to the reaction mixture. The reaction was stirred at room temperature for 28 h. After completion of reaction, 12 ml MeOH was added to the reaction mixture to get a white precipitate. It was allowed to settle down for 15 min. The precipitate was collected after centrifugation at 7200 rpm for 5 min. The above step was repeated twice to remove all the unreacted starting materials.
CB[7]-PEG-TCO
[0072] Synthesis of CB[7] conjugated phalloidin: Amino phalloidin (120 μg, 60 μΐ from 2 mg ml-1 stock solution in dry DMF, 0.1523 μιηοΐ) was taken in 1.5 ml microcentrifuge tube and 5 μΐ DMF solution containing 0.106 μΐ Et3N was added to it. Afterward, 30.34 μΐ Tetrazine- HS ester (from a stock solution of 10 mg ml-1 in DMF, 0.7615 μιηοΐ) was added the above reaction mixture and stirred at room temperature for 3 h to obtain Phalloidin-tetrazine conjugate and purified later by using HPLC. Purified Phalloidin- tetrazine conjugate (30 μg, 0.038 μιηοΐ) in 50 μΐ water was taken in 1.5 ml microcentrifuge tube and CB[7]-PEG-TCO (130 μg, 39.1 μΐ from 3.33 mg ml-1 stock solution in H20, 0.076 μιηοΐ) was added to it and stirred at room temperature for overnight to prepare CB[7] conjugated phalloidin (Scheme 2).
CB[71 conjugated phalloidin
Scheme 2: Synthesis of CB[7] conjugated phalloidin
[0073] Hexamethylene diamine conjugated with Cy5
[0074] Synthesis of thiol derivative of Hexamethylene diamine (HMD)
0°C→-RT Compound 4
Compound 6 Compound 5
Scheme 3: Synthesis of thiol derivative of HMD
[0075] Synthesis of Compound 1: Tetra ethylene glycol (TEG, 10 g, 51.22 mmol) was taken in 250 ml RB Flask. 130 ml acetonitrile and triethyl amine (7.13 ml, 51.22 mmol) were added to it. Tosyl chloride (9.76 g, 51.22 mmol), dissolved in 20 ml acetonitrile was added drop wise from dropping funnel over 1 h keeping the reaction mixture at 0°C. After the addition, the reaction mixture was stirred at room temperature for 14 h. During the reaction, a white precipitate of triethyl ammonium hydrochloride was formed. After completion of reaction, the precipitate was filtered and washed with acetonitrile. The acetonitrile was evaporated and the compound was purified using flash silica (230-400 mesh) column (eluent: ethyl acetate (EtOAc)/hexane, gradient elution from 0 to 80%).
[0076] Synthesis of Compound 2: A solution of NaOH (0.864 g, 21.6 mmol) in 8 ml water was added to a solution of triphenylmethanethiol (3.98 g, 14.402 mmol) in a mixture of toluene/ethanol (EtOH) (1: 1 v/v, 50 ml). Compound 1 (5.019 g, 14.402 mmol) was dissolved in a second solution of toluene/EtOH (1: 1 v/v, 50 ml), which was then added to the triphenylmethanethiol solution in one portion. The reaction mixture was stirred at room temperature for 18 h. After completion of reaction (monitored by TLC) the reaction mixture was poured into 20 ml saturated NaHC03 solution and extracted with diethyl ether (Et20) (3 x 40 ml). The combined organic layers were washed with brine (3 x 40 ml), dried over Na2S04 and solvent was removed under vacuum to give a pale-yellow oil. The crude product was purified by silica column (60-120 mesh) chromatography (eluent: EtOAc/hexane, 1 :2→3 : 1) to yield compound 2 as a pale-yellow oil.
[0077] Synthesis of Compound 3: A solution of compound 2 (5.43 g, 12.0 mmol) and triethylamine (2.5 ml, 18 mmol) in 60 ml dry dichloromethane (DCM) was stirred below 5°C under argon atmosphere. Methanelsulfonyl chloride (1.68 ml, 24.0 mmol) was added in dropwise fashion while maintaining the temperature below 5°C. The reaction mixture was stirred for 30 min below 5°C and then allowed to stir at room temperature for another 12 h. After completion of reaction (monitored by TLC), the resulting residue was diluted to 100 ml with DCM and washed with 0.1 M HC1 (2 x 25 ml), saturated NaHC03 solution (2 x 25 ml), and brine solution (1 x 25 ml). The organic layer was dried over Na2S04 and concentrated under reduced pressure. The crude product was purified by flash silica column (eluent: EtOAc/hexane 1: 1) to yield compound 3 as a pale-yellow oil.
[0078] Synthesis of Compound 4: Compound 4 was synthesized by following a literature reported preocedure6. Hexamethylenediamine (HMD, 13.3 g, 114.5 mmol) was taken in 120 ml chloroform. Di-tert-butyldicarbonate (2.5 g, 11.45 mmol) dissolved in 30 ml chloroform was added to the reaction mixture over two h using dropping funnel keeping the reaction mixture below 5°C. Then the reaction mixture was stirred at room temperature for 12 h. During the reaction a white precipitate was formed which was filtered. The filtrate was concentrated to 50 ml using rotary evaporator, washed with 0.1N HC1 (2 x 50 ml), water (4 x 50 ml) and brine solution (2 x 30 ml). The organic layer was filtered through Na2S04 to give compound 4.
[0079] Synthesis of Compound 5: Compound 4 (812.1 mg, 3.7545 mmol) was first dissolved in 2 ml dry DCM/mehanol (MeOH) (1: 1 v/v) and placed in a 10 ml round bottom (RB) flask. Compound 3 (400 mg, 0.7509 mmol) was dissolved in 2 ml of dry DCM/MeOH (1:1 v/v) in a vial and added to it. The reaction mixture was heated to 50°C and stirred for 48
h. After completion of reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure, diluted with DCM and directly charged on a flash silica column.
[0080] Synthesis of Compound 6: Compound 5 (300 mg, 0.4613 mmol) was dissolved in 4.5 ml Dry DCM in a 10 ml RB flask. The solution was purged with nitrogen and an excess of trifluoro acetic acid (TFA, 710.8 μΐ, 9.226 mmol) was added. During the addition period of TFA, the color of the solution turned to yellow. Subsequently, triisopropylsilane (TIPS, 472.52 μΐ, 2.3065 mmol) was added to the reaction mixture and the color of mixture slowly changed to colorless. Then the reaction mixture was allowed to stir at room temperature for 6 h under nitrogen atmosphere. The volatile components (DCM, TFA and TIPS) were then removed under reduced pressure. The pale-yellow residue was purified by washing with hexane (3 x 10 ml) and diethyl ether (3 x 10 ml). A viscous colorless liquid was obtained after drying under high vacuum.
[0081] Synthesis of HMD-Cy5: Cy5 maleimide (66.67 μg, 50 μΐ from 1.33 mg ml-1 stock solution in PBS (pH 7.4), 0.0876 μιηοΐ) was taken in 1.5 ml microcentrifuge tube. A stock solution of Compound 6 (16.4 μg, 50 μΐ from 0.82 mg ml-1 stock solution in PBS (pH 7.4), 0.1314 μιηοΐ) was added to the Cy5-maleimide solution and stirred for overnight at room temperature. After that the reaction mixture was directly injected to reverse phase HPLC for purification to yield HMD-Cy5 (90% from HPLC chromatogram).
[0082] Imaging of F-actin using phalloidin as small molecule targeting moiety
[0083] For labeling F-actin, fixed (4% PFA) and permeabilized cells were incubated with 2 μΜ solution of CB[7] conjugated phalloidin for 12 h at 4°C. Excess phalloidin was removed and imaging was performed after washing the cells once with PBS. The fluorescence images were acquired using an inverted Zeiss ELYRA PS 1 microscope, capable of illuminating the sample with TIRF illumination mode. The microcope was fitted with a definite focus system to eliminate z drift. Two lasers have been used for excitation: 561 nm (200 mW) and 642 nm (150 mW). Imaging was performed using a Zeiss oil-immersion TIRF objective (alpha Plan-apochromat DIC lOOx/1.46 Oil DIC M27, numerical aperture (NA) 1.46 oil). Fluorescence light was spectrally filtered with emission filters (MBS-561+EF BP 570-650/LP 750 for laser line 561 and MBS-642+EF LP 655 for laser line 642) and imaged on an electron-multiplying charge-coupled device (EMCCD) camera (Andor iXon DU897, quantum yield >90%, 512 x 512 pixels). In vitro single molecule data was then analysed by using a custom-programmed software package named 'Picasso' . Super-resolution 2D and 3D images were reconstructed using PALM analysis package for Zen software (Zeiss). The drift
correction was implemented using fiducial based method. Additional softwares have been used for color adjustment (ImageJ) and data analysis (Origin 9.0).
[0084] FIG. 3A illustrates an exemplary super-resolution image of F-actin fibers in MEF cells stained with CB[7] conjugated phalloidin (scale bar 1 μιη). FIG. 3B illustrate an exemplary image (zoomed-in view, scale bar 500 nm) depicting F-actin fibers in MEF cells utilizing traditional imaging technique (diffraction limited image). FIG. 3D illustrates an exemplary graph depicting comparison of super-resolution fluorescence microscopy of F- actin, cross-section profile of a single filament dl in FIG. 3C, that shows a Gaussion fit with FWHM of 29.87+2.91 nm) in accordance with an embodiment of the present disclosure, with the results obtained from traditional imaging technique.
[0085] EXAMPLE 2
[0086] Site directed delivery (cytosolic delivery) of membrane impermeable Phalloidin derivative into the HeLa cells utilizing a dynamic host-guest interactive system including CB[7] as a host molecule conjugated with Phalloidin (therapeutic agent), and hexamethylene diamine (a guest molecule) conjugated with gold nanoparticles (a targeting moiety)
[0087] Synthesis of 2 nm Gold nanoparticles (AuNPs): Pentane thiol capped gold nanoparticles were synthesised following Brust Schiffrin method as reported in "preparation of 2nm gold nanoparticles for in vivo and in vitro applications, Methods Mol. Biol. 2013, 1025, 3-8".
[0088] Synthesis of hexamethylene diamine (HMD) functionalized Gold nanoparticles: 5 mg of 2 nm pentane thiol capped AuNPs were taken in 1 ml dry DCM (DCM purged with N2) to vial containing magnetic stirring bar. 30 mg of Compound 6 thiolated ligand was weighed, immediately transferred and dissolved in 1 ml of Dry DCM. Mix them and stirred at room temperature for 60 h. Solvents were removed in a rotary evaporator. Solid residue was purified by hexane followed by DCM by the support of sonication and centrifugation, redispersed in Milli-Q water and dialysed against water for 2 days. The dialysed nanoparticle was concentrated using Amicon lOKDa MWCO filter. Portion was dissolved in D20 and characterized.
[0089] Preparation of live cell: HeLa cells (epithelial, human cervical cancer cell line) were used for the live-cell experiment. The cells were cultured in a humidified atmosphere (5% C02) at 37°C and grown in Dulbecco's Modified Eagle's Medium (DMEM, high glucose) supplemented with 10% fetal bovine serum (FBS) (Gibco, USA), 2 mM Glutamax (Invitrogen, USA) and 1% antibiotics (100 U/ml penicillin, 100 μg/ml streptomycin and 0.25
μg/ml amphotericin) (Gibco, USA). At -80% confluence, the cells were washed 3 times with DPBS (Gibco, USA), trypsinized and suspended in culture medium. Afterward, cells were then counted and then in a typical experiment, -25,000 cells/well were plated in 8- well chamber slide system (Eppendorf). The cells were then maintained again in a humidified atmosphere (37°C, 5% C02) for 24 h to reach -60% confluence. Thereafter, cells were used for imaging experiment.
[0090] Live cell delivery of phalloidin-CB[7] conjugate: Culture media was removed from the chamber wells and cells were washed twice with DPBS (pH 7.4). 2 μΜ concentration of Phalloidin-CB[7] conjugate was assembled with HMD associated with gold nanoparticles at a concentration ratio of 10: 1 and added to the cells. Cells were then maintained at 37°C with 5% C02 in a humidified atmosphere for 3 hours. After 3 hours of incubation, cells were washed twice with DPBS.
[0091] EXAMPLE 3
[0092] Site directed delivery (cytosolic delivery) of membrane impermeable Phalloidin derivative into the HeLa cells utilizing a dynamic host-guest interactive system including CB[7] as a host molecule conjugated with Phalloidin (therapeutic agent), and hexamethylene diamine (a guest molecule) conjugated with gold nanoparticles (a targeting moiety) with imaging thereof.
[0093] HMD functionalized Gold nanoparticles and CB[7] conjugated with Phalloidin were prepared in accordance with the procedure provided in Example 2 above. Further, HMD conjugated Rhodamine was prepared to effect imaging of F-actin fibers in MEF cells.
[0094] Synthesis of HMD-Rhodamine: Rhodamine maleimide (37.62 μg from 1.33 mg ml-1 stock solution in PBS (pH 7.4), 0.068 μιηοΐ) was taken in 1.5 ml microcentrifuge tube. A stock solution of Compound 6 (63 μΐ from 1 mg ml-1 stock solution in PBS (pH 7.4), 0.2042 μιηοΐ) was added to the Rhodamine maleimide solution and stirred for overnight at room temperature. After that the reaction mixture was directly injected to HPLC for purification to yield HMD-Rhodamine.
[0095] Imaging with super-resolution fluorescence microscopy technique: After nanoparticle mediated delivery of Phalloidin-CB[7] conjugate utilizing methodology as provided in Example 2 hereinabove, cells were immediately incubated with 10 nM PBS solution of silicon Rhodamine conjuagted HMD imager. The imaging was started immediately after the imager incubation. The images were captured using an inverted Zeiss ELYRA PS 1 microscope, capable to illuminating the sample with TIRF illumination mode. The microscope was fitted with a definite focus system to eliminate z drift. 642 nm (150
mW) laser has been used for excitation of Alexa 647 dye. Imaging was performed using a Zeiss oil-immersion TIRF objective (alpha Plan-apochromat DIC lOOx/1.46 Oil DIC M27, numerical aperture (NA) 1.46 oil). Fluorescence light was spectrally filtered with emission filter (MBS-642+EF LP 655 for laser line 642) and imaged on an electron -multiplying charge-coupled device (EMCCD) camera (Andor iXon DU897, quantum yield >90%, 512 x 512 pixels). Camera readout rate was 1 MHz at 16 bit. The recorded image dimension was 51.10 μιη x 51.10 μιη. EMCCD camera gain was kept at 200 during image acquisition. Laser power density of ~ 138 W/cm2 was used to excite the fluorophore molecules. Power denisty was estimated from the field of view and the laser power at the back focal plane of the objective. Super-resolution images were reconstructed using PALM analysis package for Zen software (Zeiss). FIG. 4A illustrate an exemplary image depicting super-resolution fluorescence microscopy of phalloidin targeted F-actin (scale bar: 5 μιη), in accordance with an embodiment of the present disclosure. Non-covalent interaction mediated delivery of phalloidin allowed the access to the CB[7] functionality for imaging via super-resolution fluorescence microscopy technique. After target binding, incubation of the cells with silicon rhodamine labeled HMD imager resulted in spontaneous blinking. FIG. 4B illustrate an exemplary image of phalloidin targeted F-actin (scale bar: 5 μιη) utilizing traditional imaging technique. As can be seen from FIG. 4A and FIG. 4B, a significant improvement of resolution and much sharper image from live cell could be obtained utilizing the technique in accordance with embodiments of the present disclosure. FIG. 4C illustrates an exemplary graph depicting comparison of super-resolution fluorescence microscopy of phalloidin targeted F-actin (cross-section profile of an actin filament - region marked with a square in FIG. 4A and FIG. 4B), in accordance with an embodiment of the present disclosure, with the results obtained from traditional imaging technique. FIG. 4C shows a Gaussion fit with full width at half maximum (FWHM) of 59.39+1.86 nm for image obtained in accordance with embodiment of the present disclosure as compare to a FWHM of 358.27+8 nm for the diffraction limited image.
[0096] While the foregoing describes various embodiments of the invention, other and further embodiments of the invention may be devised without departing from the basic scope thereof. The scope of the invention is determined by the claims that follow. The invention is not limited to the described embodiments, versions or examples, which are included to enable a person having ordinary skill in the art to make and use the invention when combined with information and knowledge available to the person having ordinary skill in the art.
ADVANTAGES OF THE INVENTION
[0097] The present disclosure provides a dynamic host-guest interactive system that can overcomes the deficiencies associated with the prior art.
[0098] The present disclosure provides a dynamic host-guest interactive system for imaging.
[0099] The present disclosure provides a dynamic host-guest interactive system for drug delivery.
[00100] The present disclosure provides an imaging and a drug delivery system that can utilize supramolecular host-guest interaction.
[00101] The present disclosure provides an imaging and a drug delivery system that exhibits desired specificity.
[00102] The present disclosure provides an imaging and a drug delivery system that gives image of the biological system without utilization of any of an external stimuli or an additive.
[00103] The present disclosure provides an imaging and a drug delivery system that offers improved resolution without any complex instrumentation or specialized experimental conditions.
[00104] The present disclosure provides an imaging and a delivery system that is easy to implement.
[00105] The present disclosure provides an imaging and a delivery system that is cost- effective.
Claims
laim:
A dynamic host-guest interactive system, said system comprising:
at least one host molecule; and
at least one guest molecule,
wherein the at least one host molecule interacts with the at least one guest molecule through non-covalent forces, and wherein the at least one host molecule is associated with any or a combination of at least one targeting moiety and at least one therapeutic agent with proviso that,
when the host molecule is associated with the at least one targeting moiety, the guest molecule is associated with at least one imager,
when the host molecule is associated with the at least one therapeutic agent, the guest molecule is associated with at least one targeting moiety, and when the host molecule is associated with a combination of the at least one therapeutic agent and the at least one targeting moiety, the guest molecule is associated with at least one imager.
The system as claimed in claim 1, wherein the at least one host molecule is selected from any or a combination of cucurbituril, cyclodextrins, calixarenes, pillararenes, porphyrins, metallacrowns, crown ethers, cyclotriveratrylenes, cryptophanes, cyclophanes and carcerands.
The system as claimed in claim 1, wherein the cucurbituril is CB[7], and wherein the association of CB[7] with the at least one therapeutic agent increases solubility of said at least one therapeutic agent, further wherein the association of CB[7] with the at least one therapeutic agent affords protection to said at least one therapeutic agent from degradation in a biological medium.
The system as claimed in claim 1, wherein said system affords site specific delivery of the at least one therapeutic agent by targeting tissue and organelles.
The system as claimed in claim 1, wherein said system affords a convenient route to any or a combination of cell surface engineering and cell surface modification.
The system as claimed in claim 1, wherein the host molecule associated with said at least one therapeutic agent exhibits capability to bind with proteins to afford protection to pharmacokinetics of the at least one therapeutic agent.
7. The system as claimed in claim 1, wherein said system affords delivery of any or a combination of DNA, RNA, siRNA and protein by non-covalent interaction thereof with the host molecule.
8. The system as claimed in claim 1, wherein the at least one guest molecule is selected from any or a combination of propylamine, hexamethylenediamine and a damantylamine.
9. The system as claimed in claim 1, wherein the at least one guest molecule is associated with the at least one imager through a first linking moiety, and wherein the at least one host molecule is associated with the at least one targeting moiety through a second linking moiety, further wherein the first linking moiety and the second linking moiety is selected, independently, from any or a combination of tram'-cyclooctene (TCO), 1,2,4,5-tetrazine (TZ) and N-hydroxysuccinimide (NHS).
10. The system as claimed in claim 1, wherein the interaction of the at least one guest molecule associated with the imager with the at least one host molecule through the non-covalent forces effects ON-state of the imager associated with the guest molecule when subjected to points accumulation for imaging in nanoscale topography (PAINT).
11. The system as claimed in claim 1, wherein the imager associated with the at least one guest molecule exhibits OFF-state in an event of absence of interaction between the at least one guest molecule and the at least one host molecule through the non-covalent forces when subjected to points accumulation for imaging in nanoscale topography (PAINT).
12. The system as claimed in claim 1, wherein the ON-state and OFF-state of the imager associated with the at least one guest molecule is effected without utilization of any of an external stimuli and an additive.
13. A dynamic host-guest interactive system comprising:
at least one host molecule; and
at least one guest molecule,
wherein the at least one host molecule is associated with at least one targeting moiety, and wherein the at least one guest molecule is associated with at least one imager, and wherein the at least one imager associated with the at least one guest molecule exhibits OFF-state in an event of absence of non-covalent forces operative between the at least one guest molecule and the at least one host molecule, and wherein non-covalent interaction of the at least one guest molecule associated with the imager with the at least one host molecule effects ON-state of
the imager associated with the guest molecule, when subjected to points accumulation for imaging in nanoscale topography (PAINT).
14. The system as claimed in claim 8, wherein the at least one host molecule is selected from any or a combination of cucurbiturils, cyclodextrins, calixarenes, pillararenes, porphyrins, metallacrowns, crown ethers, cyclotriveratrylenes, cryptophanes, cyclophanes and carcerands.
15. The system as claimed in claim 8, wherein the at least one guest molecule is selected from any or a combination of propylamine, hexamethylenediamine and adamantylamine.
16. The system as claimed in claim 8, wherein the at least one imager is selected from any or a combination of Alexa Fluor, Cy5, Atto 655 and Rhodamine.
17. The system as claimed in claim 8, wherein the at least one targeting moiety is selected from any or a combination of antibodies and small molecules.
18. A dynamic host-guest interactive system comprising:
at least one host molecule; and
at least one guest molecule,
wherein the at least one host molecule is associated with at least one therapeutic agent, and wherein said at least one guest molecule is associated with at least one targeting moiety, and wherein said at least one guest molecule is associated with said at least one targeting moiety through covalent bond.
19. The system as claimed in claim 13, wherein the at least one host molecule is selected from any or a combination of cucurbiturils, cyclodextrins, calixarenes, pillararenes, porphyrins, metallacrowns, crown ethers, cyclotriveratrylenes, cryptophanes, cyclophanes and carcerands.
20. The system as claimed in claim 13, wherein the at least one guest molecule is selected from any or a combination of propylamine, hexamethylenediamine and adamantylamine.
21. The system as claimed in claim 13, wherein the at least one targeting moiety is selected from any or a combination of antibodies and small molecules.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201741029226 | 2017-08-17 | ||
IN201741029226 | 2017-08-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019034945A1 true WO2019034945A1 (en) | 2019-02-21 |
Family
ID=63557654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2018/055375 WO2019034945A1 (en) | 2017-08-17 | 2018-07-19 | Dynamic host-guest interactive system |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2019034945A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111320899A (en) * | 2020-03-13 | 2020-06-23 | 四川大学 | Kit and application thereof in preparation of visual organic solvent indicator and writing of confidential documents |
CN113185660A (en) * | 2021-04-14 | 2021-07-30 | 南通大学 | Covalent organic framework based on pillar arene and preparation method and application thereof |
CN115626930A (en) * | 2022-10-20 | 2023-01-20 | 贵州大学 | Synthetic method and application of seven-element cucurbituril-truxene derivative |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110076469A (en) * | 2009-12-29 | 2011-07-06 | 포항공과대학교 산학협력단 | Preparation method of self assembling drug and cell delivery system, and self assembling drug and cell delivery system prepraed therefrom |
WO2012051407A2 (en) * | 2010-10-13 | 2012-04-19 | University Of Maryland, College Park | Molecular containers and methods of making and using same |
-
2018
- 2018-07-19 WO PCT/IB2018/055375 patent/WO2019034945A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110076469A (en) * | 2009-12-29 | 2011-07-06 | 포항공과대학교 산학협력단 | Preparation method of self assembling drug and cell delivery system, and self assembling drug and cell delivery system prepraed therefrom |
WO2012051407A2 (en) * | 2010-10-13 | 2012-04-19 | University Of Maryland, College Park | Molecular containers and methods of making and using same |
Non-Patent Citations (12)
Title |
---|
"preparation of 2nm gold nanoparticles for in vivo and in vitro applications", METHODS MOL. BIOL., vol. 1025, 2013, pages 3 - 8 |
AGASTI ET AL., CHEM. SCI., vol. 8, 2017, pages 3080 - 3091 |
BETZIG, E. ET AL.: "Imaging intracellular fluorescent proteins at nanometer resolution", SCIENCE, vol. 313, 2006, pages 1642 - 1645 |
HELL, S.W.: "Far-field optical nanoscopy", SCIENCE, vol. 316, 2007, pages 1153 - 1158, XP008108384, DOI: doi:10.1126/science.1137395 |
HELL, S.W.; WICHMANN, J.: "Breaking the diffraction resolution limit by stimulated emission: stimulated emission-depletion fluorescence microscopy", OPT. LETT., vol. 19, 1994, pages 780 - 782, XP000449464 |
HUANG, B.; JONES, S. A.; BRANDENBURG, B.; ZHUANG, X.: "Whole-cell 3D STORM reveals interactions between cellular structures with nanometer-scale resolution", NAT. METHODS, vol. 5, 2008, pages 1047 - 1052, XP055417303, DOI: doi:10.1038/nmeth.1274 |
HYUNTAE JUNG ET AL: "Theranostic systems assembledon demand by host-guest chemistry", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 32, no. 30, 24 June 2011 (2011-06-24), pages 7687 - 7694, XP028261596, ISSN: 0142-9612, [retrieved on 20110630], DOI: 10.1016/J.BIOMATERIALS.2011.06.060 * |
JUNGMANN ET AL., NANO LETT., vol. 10, 2010, pages 4756 - 4761 |
KUO ET AL., J. AM. CHEM. SOC., vol. 133, 2011, pages 4664 - 4667 |
LIPING CAO ET AL: "Cucurbit[7]uril Containers for Targeted Delivery of Oxaliplatin to Cancer Cells", ANGEWANDTE CHEMIE, vol. 125, no. 46, 13 September 2013 (2013-09-13), DE, pages 12255 - 12259, XP055522154, ISSN: 0044-8249, DOI: 10.1002/ange.201305061 * |
SCHOEN ET AL., NANO LETT., vol. 11, 2011, pages 4008 - 4011 |
SHARONOV ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 18911 - 18916 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111320899A (en) * | 2020-03-13 | 2020-06-23 | 四川大学 | Kit and application thereof in preparation of visual organic solvent indicator and writing of confidential documents |
CN113185660A (en) * | 2021-04-14 | 2021-07-30 | 南通大学 | Covalent organic framework based on pillar arene and preparation method and application thereof |
CN113185660B (en) * | 2021-04-14 | 2023-08-22 | 南通大学 | Covalent organic framework based on column arene and preparation method and application thereof |
CN115626930A (en) * | 2022-10-20 | 2023-01-20 | 贵州大学 | Synthetic method and application of seven-element cucurbituril-truxene derivative |
CN115626930B (en) * | 2022-10-20 | 2024-04-09 | 贵州大学 | Synthesis method and application of seven-membered cucurbituril-trimeric indene derivative |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lukinavicius et al. | Fluorogenic probes for multicolor imaging in living cells | |
Wang et al. | Self-assembly-induced far-red/near-infrared fluorescence light-up for detecting and visualizing specific protein–peptide interactions | |
Grossi et al. | Lysosome triggered near-infrared fluorescence imaging of cellular trafficking processes in real time | |
US9835558B2 (en) | Aggregation-induced emission luminogen having an peptide sequence and its uses thereof | |
Eisele et al. | Fine-tuning DNA/albumin polyelectrolyte interactions to produce the efficient transfection agent cBSA-147 | |
WO2019034945A1 (en) | Dynamic host-guest interactive system | |
Guo et al. | DNA nanopore functionalized with aptamer and cell-penetrating peptide for tumor cell recognition | |
O’Connell et al. | Cyanine5-doped silica nanoparticles as ultra-bright immunospecific labels for model circulating tumour cells in flow cytometry and microscopy | |
Wu et al. | Fluorescent polymer dot-based multicolor stimulated emission depletion nanoscopy with a single laser beam pair for cellular tracking | |
Wang et al. | A reduction-responsive liposomal nanocarrier with self-reporting ability for efficient gene delivery | |
Sasmal et al. | Dynamic host–guest interaction enables autonomous single molecule blinking and super-resolution imaging | |
US20180372632A1 (en) | Devices, compositions and methods for imaging with raman scattering | |
Li et al. | A luminescent lanthanide approach towards direct visualization of primary cilia in living cells | |
Yang et al. | A zwitterionic near-infrared dye linked TrkC targeting agent for imaging metastatic breast cancer | |
Ghanam et al. | Single molecule localization microscopy for studying small extracellular vesicles | |
Wu et al. | Cancer cell-selective aggregation-induced emission probe for long-term plasma membrane imaging | |
Lee et al. | In vivo simultaneous imaging of plasma membrane and lipid droplets in hepatic steatosis using red-emissive two-photon probes | |
EP3960817A1 (en) | Photoactivatable fluorescent dyes with hydrophilic caging groups and their use | |
Capodilupo et al. | Thiophene-based fluorescent probes with low cytotoxicity and high photostability for lysosomes in living cells | |
Han et al. | A labeling strategy for living specimens in long-term/super-resolution fluorescence imaging | |
JP6456592B2 (en) | Fluorescence lifetime imaging probe | |
WO2019183348A1 (en) | Devices, compositions and methods for imaging with raman scattering and for super-multiplex vibrational imaging | |
CN109311914B (en) | Lanthanide tool box for organelle specific molecular imaging | |
Yuan et al. | Real-time imaging of viscosity in the mitochondrial matrix by a red-emissive molecular rotor | |
Lapidot et al. | α¯ Aminoisobutyric Acid Leads a Fluorescent syn-bimane LASER Probe Across the Blood-brain Barrier |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18769229 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18769229 Country of ref document: EP Kind code of ref document: A1 |